PeptideDeepDiveMOTS-c Peptide: Evidence, Legal Status & How It Compares
MOTS-c stands apart from the other peptides reviewed by the FDA in 2026 — it’s studied for metabolic function, not tissue repair, and has a marginally larger human evidence base. Here’s what’s actually known.
The Short Answer
MOTS-c is a mitochondrial-derived peptide, encoded within the mitochondrial genome rather than nuclear DNA. Unlike BPC-157 and TB-500, it isn’t studied for tissue repair — its research focus is metabolic function, insulin sensitivity, and exercise-related cellular signalling.
MOTS-c is not FDA-approved for any use and has no marketing authorisation anywhere in the UK or EU. It was one of four compounds (alongside BPC-157, TB-500 and KPV) reviewed by the FDA’s Pharmacy Compounding Advisory Committee in July 2026.
How It’s Thought to Work
MOTS-c is studied for its apparent role as a regulator of metabolic homeostasis, with proposed effects on AMPK activation, insulin sensitivity, and mitochondrial function under metabolic stress. Interest in MOTS-c stems partly from research on mitochondrial-derived peptides as a broader class linked to aging and metabolic health.
What the Evidence Actually Shows
Of the four peptides reviewed together by the FDA in July 2026, MOTS-c has a marginally larger human evidence base than BPC-157 or KPV — some small human studies have looked at MOTS-c levels and metabolic markers. That said, “marginally larger” is a low bar: this remains early-stage research, not the kind of controlled trial evidence needed to establish clinical efficacy for any specific use.
No validated human dosing has been established through clinical trials, and long-term human safety data remains sparse. This article does not provide dosing guidance.
The 2026 FDA Story
MOTS-c had no FDA drug approval and no USP/NF monograph, sold as a “research chemical” alongside the other peptides on this site.
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed MOTS-c alongside BPC-157, TB-500 and KPV for potential inclusion on the Category 1 bulk drug substances list. As of this writing, no final decision has been published.
MOTS-c is not FDA-approved for any use and has no recognized pharmacopeial monograph. Its inclusion in the July 2026 PCAC review means its compounding status could change, but as of this writing it remains outside both the permitted and explicitly restricted compounding categories.
Is MOTS-c Legal in the UK, Ireland, Germany & the EU?
The regulatory picture mirrors the other three PCAC-reviewed peptides closely, since none has been evaluated as a medicine in these jurisdictions. None of the below is legal advice.
No UK marketing authorisation and not a licensed medicine under the Human Medicines Regulations 2012. Not a controlled drug, but cannot be legally sold or supplied with medicinal claims.
Not authorised as a medicine by the HPRA and not scheduled as a controlled substance — the same unregulated “research use only” category as the other peptides on this site.
No marketing authorisation under the Arzneimittelgesetz. Selling it for human administration without authorisation raises the same legal issues as BPC-157, TB-500 and KPV.
Not authorised by the Dutch medicines evaluation board; sold under the same “research chemical” framing used across the EU.
Under EU medicines law (Directive 2001/83/EC), MOTS-c has no marketing authorisation in any member state.
MOTS-c vs. BPC-157 & TB-500
| Peptide | Primary research focus | Human evidence | 2026 regulatory note |
|---|---|---|---|
| MOTS-c | Mitochondrial/metabolic function | Early-stage; some small human studies | Under PCAC review, July 2026 |
| BPC-157 | Tendon, ligament, muscle & gut repair | Essentially none (1 small uncontrolled study) | Removed from FDA Category 2; PCAC review pending |
| TB-500 | Soft-tissue repair | Limited; somewhat more clinical-context data | Under PCAC review, July 2026 |
See the full recovery peptides comparison for GHK-Cu, KPV and GLP-1 medicines too.
Frequently Asked Questions
Is MOTS-c legal in the UK?
It has no UK marketing authorisation and isn’t a licensed medicine, though it also isn’t a controlled drug. It’s sold almost exclusively as a research chemical.
What is MOTS-c studied for?
Metabolic function, insulin sensitivity, and exercise-related cellular signalling — not tissue repair.
Does MOTS-c have human clinical trial data?
Some small early-stage human studies exist, giving it a marginally larger evidence base than BPC-157 or KPV, but it remains far from conclusive.
Is MOTS-c FDA approved?
No. It’s not approved for any use and was reviewed by the FDA’s Pharmacy Compounding Advisory Committee in July 2026 alongside BPC-157, TB-500 and KPV.
References
- U.S. Food and Drug Administration (2026) Meeting of the Pharmacy Compounding Advisory Committee, 23–24 July 2026 meeting notice — covering MOTS-c, BPC-157, TB-500 and KPV.
- UK Human Medicines Regulations 2012; MHRA guidance on unlicensed medicines.
- Health Products Regulatory Authority (HPRA), Ireland — authorised medicines and controlled substances listings.
- Arzneimittelgesetz (AMG), Germany — provisions on marketing authorisation of medicinal products.
- Directive 2001/83/EC on the Community code relating to medicinal products for human use.